Ping Chen,Bei Zhang,Guifang Guo,Liangping Xia,Huijuan Qiu. Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases. Oncol Transl Med, 2014, 13: 229-234.
Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases
  
View Full Text  View/Add Comment  Download reader
KeyWord:colorectal cancer (CRC); unresectable hepatic metastasis; systemic chemotherapy (SYC); hepatic arterial chemotherapy (HAIC)
Author NameAffiliation
Ping Chen State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China 
Bei Zhang State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China 
Guifang Guo State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China 
Liangping Xia State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China 
Huijuan Qiu State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China 
Hits: 2221
Download times: 1129
Abstract:
      Objective: The combination of hepatic arterial chemotherapy (HAIC) and systemic chemotherapy (SYC) has potential effect on colorectal cancer (CRC) patients with unresectable hepatic metastasis. The aim of this retrospective study was to investigate the efficacy and safety of this combined therapeutic regimen on Chinese patients based on single institute experiences. Methods: All 54 patients of this retrospective analysis were diagnosed with CRC with unresectable liver metastasis and received combined HAIC and SYC. Among the patients, 23 of them received HAIC plus SYC when they developed liver metastases as first-line treatment (Group 1), and 31 patients received HAIC plus SYC as non-first-line treatment (Group 2). The different efficacy in two groups was analyzed by SPSS 19.0. Results: The overall response rate (ORR) were 52.2% and 25.8% respectively in Groups 1 and 2 (P = 0.047), and the disease control rate (DCR) were 65.2% and 35.5% respectively in Groups 1 and 2 (P = 0.031). The median progression-free survival (PFS) were 6.8 and 3.3 months (P = 0.002), the median hepatic progression-free survival (H-PFS) were 8.8 and 3.7 months (P = 0.001), and the median overall survival (OS) were 18.8 and 13.7 months (P = 0.121) in Groups 1 and 2, respectively. No fatal reaction was observed and no significant difference of adverse reaction was found in two groups. Grade 3/4 toxic effects included neutropenia (9.7% in Group 2 only), gastrointestinal reaction (8.7% in Group 1 and 6.5% in Group 2), stomatitis (6.5% in Group 2 only) and hyperbilirubinemia (4.3% in Group 1 only). Conclusion: HAIC combined with SYC showed promising efficacy and safe profiles on CRC patients with unresectable liver metastases.
Close